Join Hossein Borghaei, DO, MS, Ramaswamy Govindan, MD, Charu Aggarwal, MD, MPH, and Jarushka Naidoo, MBBCh in a discussion on the role of immunotherapy in advanced non-small cell lung cancer without targetable mutations.
This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.
The goal of this activity is that learners will have an increased awareness of immunotherapeutic regimens as first-line treatment for NSCLC and be better able to identify and manage immune-related adverse events using a multidisciplinary approach.
Learning Objectives:
- Have increased knowledge regarding the
- Rationale for using immunotherapy in early-stage NSCLC
- Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
- Demonstrate greater confidence in their ability to
- Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC
Approximate Time to Complete: 30 minutes
Credit Available: March 11, 2022 - March 11, 2023
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
- Have increased knowledge regarding the clinical trial data evaluating immunotherapy-containing regimens for frontline treatment of advanced non-small cell lung cancer (NSCLC) without actionable mutations.
- Have increased knowledge regarding characteristics of dual immune checkpoint inhibitor therapy as frontline treatment for advanced NSCLC without actionable mutations.
- Have greater competence related to tailoring frontline treatment for patients with advanced NSCLC without actionable mutations.
- Demonstrate greater confidence in their ability to individualize frontline treatment for patients with advanced NSCLC without actionable mutations.